Investors House's Q2 report was overshadowed by the announcement that the board will propose an extr...
Redeye comments on the positive news that Saniona has outlicensed SAN2355 to Jazz Pharmaceuticals in...
Redeye clarifies the changes in the fair value range.
- Report out 26 August - Q2e EBIT of SEK 103m - Onshore wind project (147 MW), Pienava in Latvia, so...
Redeye provides a research update following the Q2 report published by Cinclus earlier today.
Redeye strengthens its positive view of Formpipe following the Q2 report.
- Strong growth and gross margin continued in Q2'25 -EBIT revised up by 11% for '25e and 4% for '26e...
- Sales -3%, adj. EBIT +1% vs. ABGSCe - Continued uncertainty in the automotive sector driven by tar...
Redeye returns with a more in-depth take on Q2 earnings.
Dovre’s Q2 results were known beforehand since the company released preliminary information about th...
Redeye provides an initial take following Paxman’s Q2 2025 report.
Investors House reported Q2 revenues of EUR 2.7m, 15% below our estimate.
Redeye has updated its near-term estimates following Kontigo Care's Q2 report and maintains a positi...
- Strong Q2 – good start with Doro Connect - '25e-'28e EBIT CAGR of 30% driven by senior subscriptio...
Redeye provides an initial comment on Scibase’s Q2 report, which came in slightly below our estimate...
Redeye considers Enviro’s Q2 report undramatic (as expected), presenting no big surprises.
Redeye give its comments on the Q2 report; After a strong Q1 report, where Payday 3 was included for...
We expect Nokian Panimo's debut earnings as a listed company to demonstrate resilience despite chall...
Redeye comments on Formpipe’s Q2 report, showing a relatively soft Lasernet ACV and somewhat higher ...
Redeye provides its initial view on Kontigo Care’s Q2 2025 results, which were broadly in line with ...
